A tumor scan told a striking story: one patient’s ovarian cancer shrank by 49.5% after treatment with an experimental drug combination, and she stayed on the trial for more than 15 months. The result comes from a small Phase I study at The University of Texas MD Anderson Cancer Center in Houston, where researchers are testing a new way to treat ovarian cancer that no longer responds to standard chemotherapy.

About one-quarter of ovarian cancers resist platinum-based chemotherapy from the start, and many others become resistant over time. For these patients, doctors often use paclitaxel, a chemotherapy drug, with bevacizumab, a targeted treatment. But cancers can also become resistant to that combination. The MD Anderson team is studying whether adding IACS-6274 can help.

The experimental drug was designed to block glutaminase-1, or GLS-1, an enzyme that helps some cancer cells use glutamine, a nutrient they rely on. IACS-6274 aims to block GLS-1 without interfering with a related enzyme, glutaminase-2, which has important roles in the body. Earlier attempts to block glutamine broadly led to side effects that limited how much treatment patients could receive.

The Phase I trial enrolled 14 people whose cancers had stopped responding to standard treatment. Thirteen had platinum-resistant ovarian cancer and could be assessed for how well the treatment worked. Nine had confirmed partial responses, meaning their tumors shrank by at least 30%. Three others had stable disease, with their cancer neither growing nor shrinking. In total, 11 of the 13 had disease control 12 weeks after treatment began.

Among 10 patients who had either a partial response or stable disease, those results lasted at least four months; some lasted nearly three years, said principal investigator Timothy Yap, a professor of Investigational Cancer Therapeutics at MD Anderson. “We saw deep and durable responses in these patients with advanced, hard-to-treat ovarian cancer,” he said.

The combination was well tolerated in this early study, with no dose-limiting toxicities, meaning no side effects severe enough to prevent treatment at the tested doses. Reported effects were mostly mild and included nausea, tiredness, hair loss, anemia, nosebleeds, changes in liver tests, low levels of infection-fighting white blood cells, and nail or vision problems. More serious cases of low white blood cell counts, high blood pressure and anemia were treated successfully.

Researchers are also looking for clues about who may benefit most. Eight of the 14 patients had a loss of ASNS, an enzyme that helps cells make a nutrient-related building block. These cancers may depend especially strongly on glutamine; six of the eight patients with ASNS loss had partial responses.

The results are encouraging, but they come from a small early-stage trial and do not yet show how the combination compares with other treatments. The study will add 15 more patients, with another expansion of 15 planned if results remain positive. The team hopes further testing will show whether targeting cancer cells’ glutamine dependence can offer a useful option for people whose ovarian cancer has few effective treatments left.